Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 486

1.

Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.

Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS.

Eur J Cancer. 2013 Nov;49(16):3486-96. doi: 10.1016/j.ejca.2013.07.006. Epub 2013 Aug 1.

PMID:
23910494
2.

Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.

Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST.

Ann Hematol. 2011 Oct;90(10):1219-23. doi: 10.1007/s00277-011-1241-0. Epub 2011 Apr 26.

PMID:
21520001
3.

Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.

Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD.

J Clin Oncol. 2013 Aug 1;31(22):2765-72. doi: 10.1200/JCO.2012.48.5938. Epub 2013 Jun 17.

PMID:
23775967
4.

Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.

Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N.

J Clin Oncol. 2010 Dec 1;28(34):5097-100. doi: 10.1200/JCO.2010.29.7531. Epub 2010 Sep 13. Retraction in: J Clin Oncol. 2011 Sep 20;29(27):3720.

PMID:
20837949
5.

Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy.

Wang YH, Fan L, Wang L, Zhang R, Xu J, Fang C, Li JY, Xu W.

Support Care Cancer. 2013 May;21(5):1265-71. doi: 10.1007/s00520-012-1656-8. Epub 2012 Nov 15.

PMID:
23151650
6.

Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.

Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lie AK, Lai CL, Kwong YL, Yuen MF.

J Clin Oncol. 2014 Nov 20;32(33):3736-43. doi: 10.1200/JCO.2014.56.7081. Epub 2014 Oct 6.

PMID:
25287829
7.

Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.

Ji D, Cao J, Hong X, Li J, Wang J, Chen F, Wang C, Zou S.

Eur J Haematol. 2010 Sep;85(3):243-50. doi: 10.1111/j.1600-0609.2010.01474.x. Epub 2010 May 20.

PMID:
20491883
8.

Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.

Liu WP, Zheng W, Song YQ, Ping LY, Wang GQ, Zhu J.

World J Gastroenterol. 2014 May 7;20(17):5165-70. doi: 10.3748/wjg.v20.i17.5165.

9.

[Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab].

Mimura N, Kojima H, Tsujimura H, Ise M, Sakai C, Fukai K, Yokosuka O, Kumagai K.

Rinsho Ketsueki. 2010 Mar;51(3):213-5. Japanese.

PMID:
20379117
10.

Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.

Wu JM, Huang YH, Lee PC, Lin HC, Lee SD.

J Clin Gastroenterol. 2009 May-Jun;43(5):496-8. doi: 10.1097/MCG.0b013e3181945942.

PMID:
19247200
11.

The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy.

Chen XQ, Peng JW, Lin GN, Li M, Xia ZJ.

Med Oncol. 2012 Jun;29(2):1237-41. doi: 10.1007/s12032-011-9974-0. Epub 2011 May 10.

PMID:
21556931
12.

Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.

Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, Wu X, Peng J, Xu B, Lin Y, Cao Y, Li H, Lin S, Liu Q, Lin T.

JAMA. 2014 Dec 17;312(23):2521-30. doi: 10.1001/jama.2014.15704.

PMID:
25514302
13.

Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.

Borentain P, Colson P, Coso D, Bories E, Charbonnier A, Stoppa AM, Auran T, Loundou A, Motte A, Ressiot E, Norguet E, Chabannon C, Bouabdallah R, Tamalet C, GĂ©rolami R.

J Viral Hepat. 2010 Nov;17(11):807-15. doi: 10.1111/j.1365-2893.2009.01239.x.

PMID:
20002298
14.

Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.

Kusumoto S, Tanaka Y, Ueda R, Mizokami M.

J Gastroenterol. 2011 Jan;46(1):9-16. doi: 10.1007/s00535-010-0331-4. Epub 2010 Oct 6. Review.

PMID:
20924616
15.

Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.

Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A.

Biol Blood Marrow Transplant. 2010 Jun;16(6):809-17. doi: 10.1016/j.bbmt.2009.12.533. Epub 2010 Jan 7.

16.

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK.

J Clin Oncol. 2009 Feb 1;27(4):605-11. doi: 10.1200/JCO.2008.18.0182. Epub 2008 Dec 15.

PMID:
19075267
17.

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM.

Ann Hematol. 2004 Dec;83(12):769-74. Epub 2004 Aug 25.

PMID:
15338194
18.

Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study.

Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, Kao WY, Chiu CF, Lin SF, Lin J, Chang CS, Tien HF, Liu TW, Chen PJ, Cheng AL; Taiwan Cooperative Oncology Group..

Hepatology. 2014 Jun;59(6):2092-100. doi: 10.1002/hep.26718. Epub 2014 Apr 14.

PMID:
24002804
19.

Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.

Chen FW, Coyle L, Jones BE, Pattullo V.

Liver Int. 2013 Sep;33(8):1203-10. doi: 10.1111/liv.12154. Epub 2013 Mar 24.

PMID:
23522150
20.

Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.

Lubel JS, Angus PW.

J Gastroenterol Hepatol. 2010 May;25(5):864-71. doi: 10.1111/j.1440-1746.2010.06243.x. Review.

PMID:
20546439

Supplemental Content

Support Center